Sugi Predict

Sugi Predict / Compounds / SCHEMBL295965

SCHEMBL295965

SCHEMBL295965

CC(C)Cc1nc2c([nH]1)c(=O)n(C)c(=O)n2C

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.66
▸ ALDH1A1 P00352 5/20 0.64
▸ HSD17B10 Q99714 2/20 0.64
▸ CYP3A4 P08684 2/20 0.64
▸ CASP1 P29466 1/20 0.64
▸ CASP7 P55210 1/20 0.64
▸ CYP2C19 P33261 4/20 0.56
▸ CYP1A2 P05177 2/20 0.56
▸ TSHR P16473 2/20 0.54
▸ MEN1 O00255 1/20 0.54
▸ PDE5A O76074 1/20 0.54
▸ BLM P54132 1/20 0.54
▸ PDE1A P54750 1/20 0.54
▸ PDE1B Q01064 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ PDE1C Q14123 1/20 0.54
▸ PABPC1 P11940 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ GAA P10253 1/20 0.52
▸ MAPT P10636 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10888855 0.88 POLB (0.62) POLBALDH1A1HSD17B10CYP3A4CASP1
SCHEMBL11227142 0.86 POLB (0.64) POLBALDH1A1HSD17B10CYP3A4CASP1
SCHEMBL2917588 0.85 PDE5A (0.74) CYP3A4CYP2C19CYP1A2TSHRMEN1
SCHEMBL16029241 0.84 ALDH1A1 (0.63) POLBALDH1A1HSD17B10CYP3A4CASP1
SCHEMBL8399660 0.82 POLB (0.59) POLBALDH1A1HSD17B10CYP3A4CASP1
SCHEMBL6503920 0.82 ALDH1A1 (0.60) POLBALDH1A1HSD17B10CYP3A4CASP1
SCHEMBL515773 0.82 POLB (0.77) POLBALDH1A1HSD17B10CYP3A4CASP1
SCHEMBL8705380 0.81 PABPC1 (0.61) POLBALDH1A1HSD17B10CYP3A4CASP1
SCHEMBL3368846 0.81 POLB (0.69) POLBALDH1A1HSD17B10CYP3A4CASP1
SCHEMBL28991327 0.81 ALDH1A1 (0.72) POLBALDH1A1HSD17B10CYP3A4CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109783-A1 ISOLATION OF ADULT MULTIPOTENTIAL CELLS BY TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE MESOBLAST, INC. (US) 2026-04-23 — — US disclosed
US-12275801-B2 Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase MESOBLAST, INC. (US) 2025-04-15 — — US disclosed
US-20240101961-A1 Multipotential Expanded Mesenchymal Precursor Cell Progeny (MEMP) and Uses Thereof MESOBLAST, INC. (US) 2024-03-28 — — US disclosed
US-20210355447-A1 Multipotential Expanded Mesenchymal Precursor Cell Progeny (MEMP) and Uses Thereof MESOBLAST, INC. (US) 2021-11-18 — — US disclosed
US-20200332023-A1 ISOLATION OF ADULT MULTIPOTENTIAL CELLS BY TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE MESOBLAST, INC. (US) 2020-10-22 — — US disclosed
US-10609922-B2 Protection of progenitor cells and regulation of their differentiation PROTEOBIOACTIVES PTY LTD (AU) 2020-04-07 — — US disclosed
EP-2380971-B1 PERIVASCULAR MESENCHYMAL PRECURSOR CELLS MESOBLAST INC (US) 2020-02-12 — — EP disclosed
US-10544394-B2 Method of increasing proliferation of bone marrow mononuclear cells expressing STRO1-dim MESOBLAST, INC. (US) 2020-01-28 — — US disclosed
US-10421946-B2 Perivascular mesenchymal precursor cells MESOBLAST, INC. (US) 2019-09-24 — — US disclosed
CN-109983119-A GLYCOENGINEERING OF E-SELECTIN LIGANDS 罗伯特·萨克斯坦 2019-07-05 — — CN disclosed
WO-2003037362-A2 MNK KINASE HOMOLOGOUS PROTEINS INVOLVED IN THE REGULATION OF ENERGY HOMEOSTASIS AND ORGANELLE METABOLISM DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung (DE) 2003-05-08 — — WO disclosed
EP-1259474-A1 CALCIUM DICARBOXYLATE ETHERS, METHODS OF MAKING SAME, AND TREATMENT OF VASCULAR DISEASE AND DIABETES THEREWITH WARNER-LAMBERT COMPANY (US) 2002-11-27 — — EP disclosed
WO-2001055078-A1 CALCIUM DICARBOXYLATE ETHERS, METHODS OF MAKING SAME, AND TREATMENT OF VASCULAR DISEASE AND DIABETES THEREWITH WARNER-LAMBERT COMPANY (GB) 2001-08-02 — — WO disclosed
EP-0820428-B1 TERMINAL CARBOXY OR TETRAZOLE GROUPS CONTAINING DIALKYL ETHERS WARNER LAMBERT CO (US) 2000-05-10 — — EP disclosed
US-5783600-A FOR ELEVATING HDL CHOLESTEROL; ANTIDIABETIC AGENTS WARNER-LAMBERT COMPANY (US) 1998-07-21 — — US disclosed
US-5756544-A ADMINISTERING TO LOWER LEVELS OF LOW DENSITY LIPOPROTEINS AND TO RAISE THE LEVELS OF HIGH DENSITY LIPOPROTEINS WARNER-LAMBERT COMPANY (US) 1998-05-26 — — US disclosed
US-5750569-A LOWERING PLASMA LIPIDS WARNER-LAMBERT COMPANY (US) 1998-05-12 — — US disclosed
EP-0820428-A1 TERMINAL CARBOXY OR TETRAZOLE GROUPS CONTAINING DIALKYL ETHERS WARNER-LAMBERT COMPANY (US) 1998-01-28 — — EP disclosed
US-5648387-A Carboxyalkylethers, formulations, and treatment of vascular diseases WARNER-LAMBERT COMPANY (US) 1997-07-15 — — US disclosed
WO-1996030328-A1 TERMINAL CARBOXY OR TETRAZOLE GROUPS CONTAINING DIALKYL ETHERS WARNER-LAMBERT COMPANY (US) 1996-10-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10609922-B2 Protection of progenitor cells and regulation of their differentiation CD44, MCL1, NES POLB 4367/4885ALDH1A1 428/4885HSD17B10 2650/4885
US-20260109783-A1 ISOLATION OF ADULT MULTIPOTENTIAL CELLS BY TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE ALPP, S100P, ALPG POLB 3770/4885ALDH1A1 1157/4885HSD17B10 4561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.